Summary
PRA Health Sciences’ Early Development Services (EDS) team of dedicated experts understands that obtaining patient safety and efficacy data early in the clinical pharmacology program plays a critical role in decision-making and lays the groundwork for efficient future development planning.
Register to download
Early Phase Studies in Patients
You may also be interested in:
standard
Early Phase Solutions
We understand the need to maximize success while minimizing time and costs. That’s why we strategically positioned our laboratories within close…
Read More
standard
Human Abuse Potential and Liability (HAP)
We’ve successfully completed more Human Abuse Potential and Liability (HAP/HAL) protocols & published more HAP studies than any other CRO.
Read More
Fact Sheet
Chemical, Manufacturing, and Control Services (CMC)
Early drug development requires manufacturing of Investigational Medicinal Products (IMP) that comply with Good Manufacturing Practice (GMP) systems…
View Resource
View all related content and resources for Early Phase Solutions
Explore Insights